NCT02627820View on ClinicalTrials.gov

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Amyloidosis
Interventions
DRUG

Isis 420915/GSK 299872

Open label study in comparison to historic control.

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER